Generic Drugs, Patents | JD Supra Law News

Court Report -- May 19, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 5/20/2013

About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. AbbVie Inc. v. Hetero USA Inc. et al. 1:13-cv-00852; filed May 15, 2013 in the District Court of Delaware - •...more

Court Report - May 05, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 5/6/2013

About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Eisai R&D Management Co., Ltd. v. Rea - 1:13-cv-00548; filed May 2, 2013 in the Eastern District of...more

Court Report - April 28, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 4/29/2013

About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Mayo Foundation for Medical Education and Research v. ARUP Laboratories, Inc. - Infringement of U.S. Patent Nos....more

Key Recommendations From The Australian Pharmaceutical Patents Review

by Carol Burnton, James Cherry | Freehills Patent Attorneys on 4/11/2013

The Australian Government has continued with the trend of reviewing Australian patent law by commissioning a review of laws relating to patents for medicines ie pharmaceutical patents. The Pharmaceutical Patents Review Panel...more

April 2013: Life Sciences Litigation Update: Will the Supreme Court Resolve Circuit Split on Settlement of ANDA Disputes?

by Quinn Emanuel Urquhart & Sullivan, LLP on 4/5/2013

On March 25, 2013, the U.S. Supreme Court heard oral argument in Federal Trade Commission v. Actavis, Inc. (Docket No. 12-416). The Actavis case centers around the debate over the type of antitrust analysis that should apply...more

Supreme Court Hears Arguments on "Pay for Delay" Agreements

by Michelle Kim, Seth Mailhot | Sheppard Mullin Richter & Hampton LLP on 4/5/2013

On March 25, 2012, the Supreme Court heard oral argument on the legality of “reverse payment” or “pay for delay” agreements between brand-name and generic drug manufacturers....more

Supreme Court of India Denies Novartis Patent Application

by Amita Gopinath | Miller Canfield on 4/4/2013

In a landmark judgment delivered on April 1, 2013, the Supreme Court of India dismissed an appeal by Novartis AG, a Swiss pharmaceutical giant, to win patent protection in India for its cancer drug Glivec. The polarizing...more

Litigation Alert: U.S. Supreme Court to Weigh In on Reverse Payment Deals

by Melanie Mayer, David Tellekson | Fenwick & West LLP on 4/3/2013

On March 25, 2013, the U.S. Supreme Court heard oral argument in FTC v. Actavis, Inc.,1 which is on appeal from the U.S. Court of Appeals for the Eleventh Circuit. This case addresses a type of patent litigation settlement...more

Supreme Court Oral Argument in FTC v. Actavis

by Kevin E. Noonan | McDonnell Boehnen Hulbert & Berghoff LLP on 4/2/2013

The Supreme Court heard oral argument in Federal Trade Commission v. Actavis (the caption for what was Federal Trade Commission v. Watson Pharmaceuticals, Inc. in the 11th Circuit opinion below) last Monday, with Deputy...more

Court Report -- April 1, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 4/1/2013

In This Issue: Millennium Pharmaceuticals Inc. v. Fresenius Kabi USA LLC et al.; Trustee's of the University of Pennsylvania v. St. Jude Children's Research Hospital; and Pfizer Inc. et al. v. Lupin Ltd. et al.....more

IP Update, Vol. 16, No. 3, March 2013

by Sarah Bro, Melissa Nott Davis, Paul Devinsky, Susan Evans, Raymond M. Gabriel, D. Jeremy Harrison, Donna M. Haynes, Sungyong “David” In, John Low, Ulrika Mattsson, Christopher May, more +Christina Ondrick, Alexander P. Ott, Philip Ou, Sara Sunderland, Rose S. Whelan, Bruce Yen, Rita Yoon | McDermott Will & Emery on 3/29/2013

In This Issue: Supreme Court - Supreme Court Finds That “First Sale” Doctrine Applies to Works Patents - Joint Actors as It Relates to Method Claim Infringement; Federal Circuit Ruling Clears Way...more

News from Abroad: Lilly Successfully Defends Zyprexa Compound Patent In Australia

by McDonnell Boehnen Hulbert & Berghoff LLP on 3/28/2013

Originally published in Wrays on March 27, 2013. On 15 March 2013, the Australian Federal Court upheld Eli Lilly's patent for the active compound in their highly successful product ZYPREXA®. Lilly successfully...more

Supreme Court Hears Oral Argument in "Pay-for-Delay" Patent Settlement Antitrust Case

by Jeffrey W. Brennan, Glenn Engelmann | McDermott Will & Emery on 3/27/2013

The Supreme Court’s ruling in Federal Trade Commission v. Actavis, Inc., will almost certainly have major implications for the viability of Federal Trade Commission and private suits alleging that pay-for-delay settlements...more

Can Big Pharma Pay To Keep Generics Off the Market?

by Aaron Kase | Lawyers.com on 3/26/2013

The U.S. Supreme Court today heard arguments over whether big pharmaceutical companies can pay generic drug manufacturers to delay their entry into the marketplace....more

Case Brief: Federal Trade Commission v. Watson Pharmaceuticals

by Kwame Mensah | McDonnell Boehnen Hulbert & Berghoff LLP on 3/26/2013

[Ed. The Supreme Court heard oral argument today in Federal Trade Commission v. Watson Pharmaceuticals. While Patent Docs will provide analysis regarding the oral argument in a subsequent post, we provide the following...more

Court Report -- March 24, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 3/25/2013

In This Issue: AstraZeneca AB et al. v. Watson Laboratories, Inc. - Florida et al.; Pharmacia & Upjohn Co. LLC et al. v. Apotex, Inc. et al.; Intendis GmbH et al. v. Glenmark Generics Ltd. et al.; and Boehringer...more

Court Report -- March 17, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 3/18/2013

In This Issue: Apotex, Inc. et al. v. Teva Pharmaceutical Industries, Ltd. et al.; Bayer Intellectual Property GmbH et al. v. Rea; Janssen Products, L.P. et al. v. Hetero Drugs, Ltd. et al.; Novartis Pharmaceuticals...more

Senators Introduce Another Bill to Ban Reverse Payment Settlement Agreements

by Kevin E. Noonan | McDonnell Boehnen Hulbert & Berghoff LLP on 3/15/2013

Last week, Senator Al Franken (D-MN) was joined by Senators David Vitter (R-LA), Dick Durbin (D-IL), Jeanne Shaheen (D-NH), and Bernie Sanders (I-VT) in introducing S. 204, the "Fair and Immediate Release of Generic Drugs...more

Court Report -- March 10, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 3/11/2013

In This Issue: G.D. Searle LLC et al. v. Lupin Pharmaceuticals, Inc. et al. and AbbVie Inc. et al. v. The Kennedy Trust Rheumatology Research....more

WLF Submits Comments on Abbott's Citizen Petition on Biosimilars

by Donald Zuhn | McDonnell Boehnen Hulbert & Berghoff LLP on 3/7/2013

Last April, Abbott Laboratories filed a Citizen Petition with the U.S. Food and Drug Administration, asking the agency to refrain from accepting biosimilar applications under the Biologics Price Competition and Innovation Act...more

New from Abroad: Broadening of UK Bolar Defence

by McDonnell Boehnen Hulbert & Berghoff LLP on 3/6/2013

Originally published in WP Thompson & Co. on March 4, 2013. On 26 February 2013, the UK government announced a proposed change to the Patents Act to exempt clinical and field trials, as well as "health technology...more

Court Report -- March 03, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 3/4/2013

In This Issue: Eli Lilly and Company et al. v. Genentech, Inc. et al.; Depomed Inc. v. Watson Laboratories Inc. - Florida et al.; Eli Lilly and Company v. Accord Healthcare Inc., USA; Endo Pharmaceuticals Inc. et al....more

In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Fed. Cir. 2013)

by Andrew Williams | McDonnell Boehnen Hulbert & Berghoff LLP on 3/1/2013

On the first day of February, the Federal Circuit rejected Impax's efforts to get out from under a preliminary injunction in a case captioned In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation. ...more

Par/Paddock Answers FTC Before Supreme Court

by Kevin E. Noonan | McDonnell Boehnen Hulbert & Berghoff LLP on 2/28/2013

Par PharmaceuticalPar/Paddock, one of the generic drug company defendants in FTC v. Actavis Inc. et al. (the "reverse payment" ANDA settlement case now before the Supreme Court) filed its reponsive brief last week. In it,...more

Court Report -- February 24, 2013

by Sherri Oslick | McDonnell Boehnen Hulbert & Berghoff LLP on 2/25/2013

In This Issue: Novartis Pharmaceuticals Corp. v. Actavis LLC et al.; Precision Biosciences Inc. et al. v. Cellectis S.A. et al.; Bayer Pharma AG v. Warner Chilcott Co., LLC et al.; Promega Corp. et al. v. Life...more

Home

Legal News

Find a Lawyer

Browse Subjects

Subscribe

Pro Services

For Reporters

Generic Drugs › Patents